Skip to content
  • HOME
  • CONTACT US
  • CAREERS
  • ONLINE TRADING PORTAL
  • English
  • 中文
Crosby

Crosby

Menu

  • NEWS & ANNOUNCEMENTS
    • SHOW ALL
    • NEWS
    • ANNOUNCEMENT
    • RESEARCH
    • EVENTS
  • WHAT WE DO
    • SALES & TRADING
    • CORPORATE FINANCE
    • ASSET MANAGEMENT
    • WEALTH MANAGEMENT
  • ABOUT US
    • THE FIRM
    • HISTORY
    • TRANSACTIONS
    • SOCIAL RESPONSIBILITY

    RESEARCH

    CROSBY Research – SIIC Environment (807 HK): Further expansion in GBA & YREB regions

    CROSBY Research – SIIC Environment (807 HK): Further expansion in GBA & YREB regions

    01 Mar 2023 SIIC reported its FY22 result with an increase in revenue by 14.3% to Rmb8.3bn (2021: Rmb7.3bn), driven by i) 10.4% YoY increase in operation revenue to Rmb3.46bn in the light of the 1.5%/3.1% YoY growth in WWT/water

    Crosby_research March 1, 2023March 1, 2023 RESEARCH Read more

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 30)

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 30)

    27 Feb 2023 Christopher Hui, secretary for HKSAR financial services and the treasury, said on Sunday that the HKEX will adopt new main board listing rules in March to allow listings by technology companies with no revenue or profit, and

    Crosby_research February 27, 2023 RESEARCH Read more

    CROSBY Research – Vincent Medical (1612 HK/Neutral): Weak respiratory sales and inventory pile-up dented bottom line

    CROSBY Research – Vincent Medical (1612 HK/Neutral): Weak respiratory sales and inventory pile-up dented bottom line

    14 Feb 2023 Vincent Medical (VM) issued a profit warning citing that its FY22 reported net profit is expected to turn into a loss of HK$15.0m to HK$20.0 as compared to a net profit of HK$60.7m in FY21. The loss,

    Crosby_research February 14, 2023 RESEARCH Read more

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 29)

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 29)

    13 Feb 2023 The Chinese medical device market is one of opportunities. It is both large and growing. China is among the ten largest medical devices markets worldwide and is regarded as one of the most promising markets. According to

    Crosby_research February 13, 2023 RESEARCH Read more

    CROSBY Research – Nagacorp (3918 HK): Recovering from the pandemic

    CROSBY Research – Nagacorp (3918 HK): Recovering from the pandemic

    10 Feb 2023 Naga’s FY22 revenue was up by 104% YoY to US$461m, mainly driven by 1) 207%/183%/87.8% YoY increase in mass market tables/mass market EGM/premium market given the fast recovery of international particularly ASEAN visitors to Cambodia and the

    Crosby_research February 10, 2023 RESEARCH Read more

    CROSBY Research – Vinda International (3331 HK): The worst should be over

    CROSBY Research – Vinda International (3331 HK): The worst should be over

    31 Jan 2023 Vinda announced FY22 results, with revenue increased by 8.1% YoY to HK$19.4bn, driven by resilient growth of 7.8%/ 9.6% YoY in the tissue/ personal care segment to HK$16.1bn/HK$3.3bn. Hit by the spreading of pandemic in China, 4Q22

    Crosby_research January 31, 2023January 31, 2023 RESEARCH Read more

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 28)

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 28)

    30 Jan 2023 A total of 484,505 tourists entered Macau during CNY this year, which was up 297% YoY, and 54% higher than 2020, though the number is only 40.3% of that in 2019. Out of the incoming tourists, 59%

    Crosby_research January 30, 2023January 31, 2023 RESEARCH Read more

    CROSBY Research – Xtep International (1368 HK/BUY): The worst has passed, a year of recovery in 2023

    CROSBY Research – Xtep International (1368 HK/BUY): The worst has passed, a year of recovery in 2023

    19 Jan 2023 Xtep reported its 4Q22 operational data with retail sell-through (including both online and offline) decline by HSD YoY. Oct saw a single digit YoY drop while Nov experienced a mid-double-digit YoY drop, as around one thirds of

    Crosby_research January 19, 2023January 31, 2023 RESEARCH Read more

    CROSBY Research – China Everbright Greentech (1257 HK/BUY): FY22 results preview

    CROSBY Research – China Everbright Greentech (1257 HK/BUY): FY22 results preview

    13 Jan 2023 CEG’s 1H22 revenue edged down by 2% YoY to HK$4,220m, and 1H22NP was down by 47% YoY to HK$372m. We expect 2H22 results could be worse than 1H22, on the back of i) deteriorating demand of its

    Crosby_research January 13, 2023February 1, 2023 RESEARCH Read more

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 27)

    CROSBY Research – Crosby Bi-noculars (Bi-weekly Issue 27)

    09 Jan 2023 HK/China border fully reopened on 8th Jan 2023. Sun Hung Kai Properties (16.HK, NR) predicts the annual footfall to increase by up to 20% at 15 of its shopping malls – including the WTC in CWB and

    Crosby_research January 9, 2023January 31, 2023 RESEARCH Read more
    • « Previous
    • Next »

    NEWS & ANNOUNCEMENTS

    • Show All
    • News
    • Announcement
    • Research
    • Events

    WHAT WE DO

    • Sales & Trading
    • Corporate Finance
    • Asset Management
    • Wealth Management

    ABOUT US

    • The Firm
    • History
    • Transactions
    • Social Responsibility
    Copyright © 2025 Crosby. All rights reserved. Theme Spacious by ThemeGrill. Powered by: WordPress.